Impact of Proposed Cuts to NIH Budget:

More Than Just About Cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

If enacted, the proposed budget reduction of $5.8 billion to the National Institutes of Health will slow research, deprive patients afflicted with cancer of hope, and deliver a devastating blow to our science workforce and the Commonwealth of Pennsylvania. This proposed reduction directly counters the wisdom of the U.S. Congress, who less than a year ago overwhelmingly passed the 21st Century Cures Act.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”
Research has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway. xxx:more
Karen E. Knudsen, PhD
Director, Sidney Kimmel Cancer Center, Thomas Jefferson University
Chi Van Dang, MD, PhD
Director, Abramson Cancer Center, University of Pennsylvania
Richard I. Fisher, MD
Director, Fox Chase Cancer Center, Temple University Health System
Edward Chu, MD
Interim director, University of Pittsburgh Cancer Institute
Dario Altieri, MD
Director, Wistar Institute Cancer Center

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login